# IN8BIO, Inc.: overview INAB · Nasdaq · CIK 1740279 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/inab.md) · [Financials](/companies/inab/financials.md) · [Filings](/companies/inab/filings.md) · [Insiders](/companies/inab/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(4.49)](/filings/0001193125-25-269447.md) | not reported | [(2.16)](/filings/0001193125-26-212135.md) | [(1.24)](/filings/0001193125-26-338012.md) | [(0.85)](/filings/0001193125-25-269447.md) | not reported | [(0.26)](/filings/0001193125-26-212135.md) | [(0.25)](/filings/0001193125-26-338012.md) | | Free cash flow | $k | [(6,111) d](/filings/0001193125-25-269447.md) | not reported | [(3,122)](/filings/0001193125-26-212135.md) | [(3,927) d](/filings/0001193125-26-338012.md) | [(3,524) d](/filings/0001193125-25-269447.md) | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.47)](/filings/0000950170-23-010997.md) | [(1.36)](/filings/0000950170-24-031486.md) | [(1.00)](/filings/0000950170-25-038738.md) | [(17.05)](/filings/0001193125-26-104181.md) | [(4.44)](/filings/0001193125-26-104181.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/inab/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $1.3m | 944,319 | | Unchanged | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $1.3m | 914,531 | | Unchanged | | [683 Capital Management, LLC](/funds/1404574.md) | 2026-06-30 | $1.0m | 724,637 | | Unchanged | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $980.4k | 695,287 | | Added +31,875 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $126.5k | 88,865 | | Unchanged | | [BIOS Capital Management, LP](/funds/1813845.md) | 2026-06-30 | $114.1k | 80,957 | | Reduced −86,848 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $102.3k | 72,550 | | Reduced −13,689 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $88.9k | 63,055 | | New +63,055 | | [OPPENHEIMER & CO INC](/funds/822581.md) | 2026-06-30 | $88.9k | 63,042 | | Added +39,009 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $62.0k | 43,570 | | Unchanged | ## Recent filings [All 409 filings](/companies/inab/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 16:11 ET | [10-Q](/filings/0001193125-26-338012.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338012 | | 2026-08-06 | 16:05 ET | [8-K](/filings/0001193125-26-337944.md) | 2.02 Results of operations | 0001193125-26-337944 | | 2026-06-01 | 06:56 ET | [8-K](/filings/0001193125-26-249684.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-249684 | | 2026-05-29 | 17:41 ET | [SCHEDULE 13D/A](/filings/0001682638-26-000008.md) | Ownership report, active investor, amended | 0001682638-26-000008 | | 2026-05-07 | 16:32 ET | [10-Q](/filings/0001193125-26-212135.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212135 | | 2026-05-07 | 16:31 ET | [8-K](/filings/0001193125-26-212128.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-212128 | | 2026-03-26 | 16:05 ET | [DEF 14A](/filings/0001193125-26-126208.md) | Proxy statement, period 2026-05-07 | 0001193125-26-126208 | | 2026-03-12 | 16:15 ET | [10-K](/filings/0001193125-26-104181.md) | Annual report, period 2025-12-31 | 0001193125-26-104181 | | 2026-03-12 | 16:10 ET | [8-K](/filings/0001193125-26-104144.md) | 2.02 Results of operations | 0001193125-26-104144 | | 2026-02-27 | 16:05 ET | [8-K](/filings/0001193125-26-082539.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-082539 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104181.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1740279 - Tickers: INAB - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.